AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23298271 — intervention group
Group type: COMPARATOR
Intervention: Single NP chemotherapy
Number of subjects: 74
Study 21910341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment (Group B)
Number of subjects: 90
Study 21910341 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus treatment (Group A)
Number of subjects: 90
Study 21910341 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of astragalus and hormone (Group C)
Number of subjects: 90
Study 21910341 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 90
Study 21910341 — intervention group
Group type: COMPARATOR
Intervention: Group C vs Group B after treatment
Number of subjects: 90
Study 19822977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 140
Study 19822977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 16986348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane
Number of subjects: 0
Study 16986348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates (oral and intravenous) such as alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid
Number of subjects: 0
Study 16986348 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and annual follow-up bone density monitoring
Number of subjects: 0
Study 16986348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 0
Study 14570792 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg, 2 ml) + i.t. normal saline
Number of subjects: 53
Study 14570792 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (0.075 mg, 1 ml) + ED normal saline
Number of subjects: 53
Study 11019424 — intervention group
Group type: EXPERIMENTAL
Intervention: Diovan (80-160 mg/day for 8 weeks)
Number of subjects: 15
Study 8776154 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free injection with the Biojector
Number of subjects: 0
Study 8776154 — intervention group
Group type: COMPARATOR
Intervention: Needle and syringe injections
Number of subjects: 0
Study 1355875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low haematocrit group (target haematocrit of 37‐38%) with 1‐4 phlebotomies
Number of subjects: 50
Study 1355875 — intervention group
Group type: COMPARATOR
Intervention: High haematocrit group (target haematocrit of 41‐42%) with 0‐3 phlebotomies
Number of subjects: 50
Study 6130246 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 20 mg/kg body weight (higher dose)
Number of subjects: 0
Study 6130246 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate 10 mg/kg body weight (lower dose)
Number of subjects: 0
Study 3942368 — intervention group
Group type: EXPERIMENTAL
Intervention: PY 108-068 (150 mg)
Number of subjects: 12
Study 3942368 — intervention group
Group type: EXPERIMENTAL
Intervention: PY 108-068
Number of subjects: 12
Study 3942368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29685013 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-37 in TB group (7.45±1.58)
Number of subjects: 46
Study 29685013 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF in TB group (8.51±1.92)
Number of subjects: 46
Study 29685013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels in TB group (24.18±1.95)
Number of subjects: 46
Study 27063308 — intervention group
Group type: EXPERIMENTAL
Intervention: FiltekTM P90
Number of subjects: 52
Study 27063308 — intervention group
Group type: COMPARATOR
Intervention: FiltekTM Z350 XT
Number of subjects: 52
Study 25055142 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation at 1 mA
Number of subjects: 40
Study 25055142 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation at 2 mA
Number of subjects: 40
Study 25055142 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 21890814 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 272
Study 21890814 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 272
Study 21890814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 20047916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol hand sanitizers with organic acids
Number of subjects: 0
Study 20047916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol hand sanitizers without organic acids
Number of subjects: 0
Study 20047916 — intervention group
Group type: COMPARATOR
Intervention: Hand washing with soap and water
Number of subjects: 0
Study 18689181 — intervention group
Group type: EXPERIMENTAL
Intervention: TST using Assufil
Number of subjects: 40
Study 18689181 — intervention group
Group type: EXPERIMENTAL
Intervention: TST using Monofil
Number of subjects: 40
Study 18689181 — intervention group
Group type: COMPARATOR
Intervention: TST (both groups)
Number of subjects: 40
Study 16393327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 microg twice daily into each nostril for 7 days)
Number of subjects: 13
Study 16393327 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (twice daily into each nostril for 7 days)
Number of subjects: 13
Study 14652007 — intervention group
Group type: COMPARATOR
Intervention: GGC repeat in Japanese population (73.7% had 16 repeats)
Number of subjects: 398
Study 14652007 — intervention group
Group type: COMPARATOR
Intervention: GGC repeat in Caucasian population (53.3% had 16 repeats)
Number of subjects: 398
Study 14652007 — intervention group
Group type: COMPARATOR
Intervention: GGC repeat in Japanese population (3.8% had 17 repeats)
Number of subjects: 398
Study 14652007 — intervention group
Group type: COMPARATOR
Intervention: GGC repeat in Caucasian population (36.2% had 17 repeats)
Number of subjects: 398
Study 14652007 — intervention group
Group type: COMPARATOR
Intervention: No Japanese had more than 18 GGC repeats
Number of subjects: 398
Study 14652007 — intervention group
Group type: COMPARATOR
Intervention: CAG repeats in Japanese population
Number of subjects: 398
Study 14652007 — intervention group
Group type: COMPARATOR
Intervention: CAG repeats in Caucasian population
Number of subjects: 398
Study 11072056 — intervention group
Group type: EXPERIMENTAL
Intervention: Referred patients (n=41)
Number of subjects: 110
Study 11072056 — intervention group
Group type: COMPARATOR
Intervention: Screen-identified patients (n=69)
Number of subjects: 110
Study 11072056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 8851900 — intervention group
Group type: EXPERIMENTAL
Intervention: Single task exposure (90-min English language transcription task)
Number of subjects: 46
Study 8851900 — intervention group
Group type: COMPARATOR
Intervention: Nontask control (90-min reading)
Number of subjects: 46
Study 8851900 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to cognitive task until late at night
Number of subjects: 46
Study 8851900 — intervention group
Group type: COMPARATOR
Intervention: Relaxed wakefulness
Number of subjects: 46
Study 1310456 — intervention group
Group type: EXPERIMENTAL
Intervention: Two puffs from MDI (90 micrograms per puff)
Number of subjects: 12
Study 1310456 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of nebulizer solution (delivered in 2 ml of buffered saline)
Number of subjects: 12
Study 1310456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6434911 — intervention group
Group type: EXPERIMENTAL
Intervention: slow, conventional four‐day method
Number of subjects: 50
Study 6434911 — intervention group
Group type: EXPERIMENTAL
Intervention: more rapid introduction protocol
Number of subjects: 50
Study 6434911 — intervention group
Group type: EXPERIMENTAL
Intervention: nasoenteric solutions
Number of subjects: 50
Study 31842188 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental cohort (223 patients) using the PRoFiT‐NU Score for predicting poor functional outcomes.
Number of subjects: 328
Study 31842188 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (105 patients) assessed using the PRoFiT‐NU Score.
Number of subjects: 328
Study 29587861 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 pre-treatment for 60 days preceding IVF-ICSI cycle
Number of subjects: 169
Study 29587861 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment (Control)
Number of subjects: 169
Study 27206690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (3 to 7 spheroids/cm²)
Number of subjects: 75
Study 27206690 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose group (10 to 30 spheroids/cm²)
Number of subjects: 75
Study 27206690 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (40 to 70 spheroids/cm²)
Number of subjects: 75
Study 27206690 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 75
Study 27206690 — intervention group
Group type: COMPARATOR
Intervention: Overall KOOS
Number of subjects: 75
Study 24981149 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal gel-based male hormonal contraceptive regimen (testosterone and Nestorone® gels)
Number of subjects: 79
Study 26286977 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation manipulation
Number of subjects: 86
Study 20447094 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mL water drinking test (WDT)
Number of subjects: 15
Study 20447094 — intervention group
Group type: COMPARATOR
Intervention: 1000-mL water drinking test (WDT)
Number of subjects: 15
Study 18990045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and vibration (EVG)
Number of subjects: 36
Study 18990045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EG)
Number of subjects: 36
Study 18990045 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 36
Study 15910140 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of altruistic citizenship behavior by men
Number of subjects: 0
Study 15910140 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding of altruistic citizenship behavior by women
Number of subjects: 0
Study 15910140 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related altruism
Number of subjects: 0
Study 12734634 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 60
Study 12734634 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 60
Study 12734634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10985009 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions related to high-risk sexual behavior (4 peer-based, interactive sessions)
Number of subjects: 196
Study 8841157 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 168
Study 8841157 — intervention group
Group type: COMPARATOR
Intervention: 5 mg amlodipine
Number of subjects: 168
Study 1737545 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin applied 4 times/day
Number of subjects: 22
Study 1737545 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied 4 times/day
Number of subjects: 22
Study 1737545 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up open-label study
Number of subjects: 22
Study 6608397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation and TENS
Number of subjects: 60
Study 6608397 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 60
Study 31535688 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT-I
Number of subjects: 658
Study 31535688 — intervention group
Group type: COMPARATOR
Intervention: Control (online sleep education)
Number of subjects: 658
Study 29611083 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 3280
Study 27583444 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel leg-curl
Number of subjects: 36
Study 27583444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring
Number of subjects: 36
Study 27583444 — intervention group
Group type: EXPERIMENTAL
Intervention: Russian belt deadlift
Number of subjects: 36
Study 27583444 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-extension conic-pulley
Number of subjects: 36
Study 23838410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation technique (1 u‐HA/PLLA plate and 4 monocortical screws and bicortical screw in each side)
Number of subjects: 44
Study 23838410 — intervention group
Group type: COMPARATOR
Intervention: Conventional plate fixation (1 u‐HA/PLLA plate and 4 monocortical screws in each side)
Number of subjects: 44
Study 23838410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 26875224 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (600 μg oral)
Number of subjects: 0
Study 21040693 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Mansonella perstans infection
Number of subjects: 1506
Study 21040693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus immunisation during pregnancy
Number of subjects: 1506
Study 21040693 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BCG scar
Number of subjects: 1506
Study 21040693 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV exposure (HIV-exposed-uninfected infants)
Number of subjects: 1506
Study 21040693 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant malaria and HIV
Number of subjects: 1506
Study 18412763 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care smoking cessation program
Number of subjects: 322
Study 18412763 — intervention group
Group type: COMPARATOR
Intervention: Brief contact care
Number of subjects: 322
Study 18412763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation services and mental health care
Number of subjects: 322
Study 18412763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation services
Number of subjects: 322
Study 16187699 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 16187699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12495134 — intervention group
Group type: EXPERIMENTAL
Intervention: New measures of the proportion of treatment effect explained by a surrogate marker
Number of subjects: 0
Study 12495134 — intervention group
Group type: COMPARATOR
Intervention: Previous measures of surrogacy suggested by Freedman, Graubard, and Schatzkin
Number of subjects: 0
Study 10088944 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry using monoclonal antibodies (HLA‐ABC‐m3, GS145.2, FD705)
Number of subjects: 304
Study 10088944 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA typing
Number of subjects: 304
Study 10088944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of flow cytometry and DNA typing
Number of subjects: 304
Study 7770362 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 55
Study 7770362 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (control group)
Number of subjects: 55
Study 2349956 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term r‐HuEPO therapy (n = 4)
Number of subjects: 8
Study 2349956 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term r‐HuEPO therapy (n = 8)
Number of subjects: 8
Study 2349956 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (n = 4)
Number of subjects: 8
Study 2349956 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO therapy (n = 8)
Number of subjects: 8
Study 668524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine (up to 480 mg/24 h) followed by Propafenon (up to 1800 mg orally) for 4 days
Number of subjects: 60
Study 668524 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon followed by Lidoflazine for 4 days
Number of subjects: 60
Study 668524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined success rate of both groups
Number of subjects: 60
Study 31544469 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted acupuncture (TA)
Number of subjects: 30
Study 31544469 — intervention group
Group type: COMPARATOR
Intervention: Non-targeted acupuncture (NTA)
Number of subjects: 30
Study 31544469 — intervention group
Group type: EXPERIMENTAL
Intervention: Male intervention (MI) group
Number of subjects: 30
Study 31859961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters polyethylene glycol
Number of subjects: 74
Study 31859961 — intervention group
Group type: COMPARATOR
Intervention: 4 liters polyethylene glycol
Number of subjects: 74
Study 28816289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion alone
Number of subjects: 36
Study 28816289 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating rapid palatal expansion and constriction
Number of subjects: 36
Study 28816289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 36
Study 26436963 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation with warfarin
Number of subjects: 187
Study 26436963 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 187
Study 26436963 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 187
Study 26436963 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 187
Study 26436963 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with reduced leaflet motion
Number of subjects: 187
Study 26436963 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal leaflet motion
Number of subjects: 187
Study 26436963 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with reduced leaflet motion (pooled registries)
Number of subjects: 187
Study 26436963 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal leaflet motion (pooled registries)
Number of subjects: 187
Study 24016506 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18801
Study 24016506 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18801
Study 20451345 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM-based joint protection education (PRISM-JP)
Number of subjects: 53
Study 18433044 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive counseling based on current clinical practice guidelines
Number of subjects: 42
Study 18433044 — intervention group
Group type: COMPARATOR
Intervention: Brief anti-smoking message
Number of subjects: 42
Study 17067352 — intervention group
Group type: EXPERIMENTAL
Intervention: Less percent days abstinent (PDA)
Number of subjects: 1193
Study 17067352 — intervention group
Group type: EXPERIMENTAL
Intervention: More drinks per drinking day (DDD)
Number of subjects: 1193
Study 17067352 — intervention group
Group type: EXPERIMENTAL
Intervention: Up to 14 days of continuous abstinence before testing
Number of subjects: 1193
Study 17067352 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of drinking at dependence levels
Number of subjects: 1193
Study 17067352 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous treatment
Number of subjects: 1193
Study 17067352 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS and DrInC scores
Number of subjects: 1193
Study 14528103 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg body weight IVIG per day for 2 consecutive days (total dose 2 g/kg)
Number of subjects: 34
Study 14528103 — intervention group
Group type: COMPARATOR
Intervention: 0.3 g/kg body weight IVIG per day for 2 consecutive days (total dose 0.6 g/kg)
Number of subjects: 34
Study 10863894 — intervention group
Group type: COMPARATOR
Intervention: Serum free IGF-I levels in children with panhypopituitarism (PAN)
Number of subjects: 48
Study 10863894 — intervention group
Group type: COMPARATOR
Intervention: Serum free IGF-I levels in children with complete growth hormone deficiencies (cGHD)
Number of subjects: 48
Study 10863894 — intervention group
Group type: COMPARATOR
Intervention: Serum free IGF-I levels in children with partial growth hormone deficiencies (pGHD)
Number of subjects: 48
Study 10863894 — intervention group
Group type: COMPARATOR
Intervention: Serum free IGF-I levels in children with idiopathic short stature (ISS)
Number of subjects: 48
Study 10863894 — intervention group
Group type: COMPARATOR
Intervention: Serum free IGF-I levels in pGHD children with IGFBP-3 SDS <= -1.3
Number of subjects: 48
Study 9347166 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus Ofloxacin (OFLX)
Number of subjects: 20
Study 9347166 — intervention group
Group type: COMPARATOR
Intervention: Interferon monotherapy
Number of subjects: 20
Study 7977882 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 71
Study 7977882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 7977882 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 71
Study 2513563 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone and flecainide
Number of subjects: 8
Study 2513563 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone and mexilitene
Number of subjects: 8
Study 2513563 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone and disopyramide
Number of subjects: 8
Study 1163095 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (1.7 mg/kg)
Number of subjects: 28
Study 1163095 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (1.7 mg/kg)
Number of subjects: 28
Study 31349833 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 1440
Study 31349833 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NIPPV)
Number of subjects: 1440
Study 31349833 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive high frequency oscillation ventilation (NHFOV)
Number of subjects: 1440
Study 29237904 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT plus TMZ (observation group)
Number of subjects: 72
Study 29237904 — intervention group
Group type: COMPARATOR
Intervention: WBRT (control group)
Number of subjects: 72
Study 25583911 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor‐Assisted Problem Solving (CAPS)
Number of subjects: 0
Study 25583911 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 0
Study 23432610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir with rifampicin in adults
Number of subjects: 95